Sodium fluoride - Mission Pharmacal

Drug Profile

Sodium fluoride - Mission Pharmacal

Alternative Names: Fluoride - Mission Pharmacal; Neosten; Slow Fluoride; SR-NaF

Latest Information Update: 04 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mission Pharmacal; University of Texas Southwestern Medical Center
  • Class Fluorides; Osteoporosis therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 02 May 2005 No development reported - Preregistration for Postmenopausal osteoporosis in USA (PO)
  • 22 May 2000 Registered for Postmenopausal osteoporosis in Germany (PO)
  • 10 Feb 1999 Preregistration for Postmenopausal osteoporosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top